New drugs and combinations for the treatment of soft-tissue sarcoma: a review

Sarcomas are a heterogeneous group of solid tumors arising from either soft tissues or bone, accounting for approximately 1% of all cancers in adults. Management of these diseases has changed little over the past 10 years, with the exception of treatment of gastrointestinal stromal tumors. Reasons f...

Full description

Bibliographic Details
Main Authors: Somaiah, Neeta, von Mehren, Margaret
Format: Online
Language:English
Published: Dove Medical Press 2012
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3514064/
id pubmed-3514064
recordtype oai_dc
spelling pubmed-35140642012-12-05 New drugs and combinations for the treatment of soft-tissue sarcoma: a review Somaiah, Neeta von Mehren, Margaret Review Sarcomas are a heterogeneous group of solid tumors arising from either soft tissues or bone, accounting for approximately 1% of all cancers in adults. Management of these diseases has changed little over the past 10 years, with the exception of treatment of gastrointestinal stromal tumors. Reasons for this stagnation include multiple histologies commonly grouped together in clinical trials limiting the understanding of benefit of treatment and limited investigation of molecular targeted therapies. More recently, advances in molecular pathogenesis, the advent of novel and targeted therapeutics, and increasing collaborations between sarcoma investigators has helped move the field forward in the right direction. Here, we review the recent data on novel agents tested for the management of adult soft-tissue sarcomas, excluding gastrointestinal stromal tumors. Dove Medical Press 2012-11-23 /pmc/articles/PMC3514064/ /pubmed/23226072 http://dx.doi.org/10.2147/CMAR.S23257 Text en © 2012 Somaiah and von Mehren, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
repository_type Open Access Journal
institution_category Foreign Institution
institution US National Center for Biotechnology Information
building NCBI PubMed
collection Online Access
language English
format Online
author Somaiah, Neeta
von Mehren, Margaret
spellingShingle Somaiah, Neeta
von Mehren, Margaret
New drugs and combinations for the treatment of soft-tissue sarcoma: a review
author_facet Somaiah, Neeta
von Mehren, Margaret
author_sort Somaiah, Neeta
title New drugs and combinations for the treatment of soft-tissue sarcoma: a review
title_short New drugs and combinations for the treatment of soft-tissue sarcoma: a review
title_full New drugs and combinations for the treatment of soft-tissue sarcoma: a review
title_fullStr New drugs and combinations for the treatment of soft-tissue sarcoma: a review
title_full_unstemmed New drugs and combinations for the treatment of soft-tissue sarcoma: a review
title_sort new drugs and combinations for the treatment of soft-tissue sarcoma: a review
description Sarcomas are a heterogeneous group of solid tumors arising from either soft tissues or bone, accounting for approximately 1% of all cancers in adults. Management of these diseases has changed little over the past 10 years, with the exception of treatment of gastrointestinal stromal tumors. Reasons for this stagnation include multiple histologies commonly grouped together in clinical trials limiting the understanding of benefit of treatment and limited investigation of molecular targeted therapies. More recently, advances in molecular pathogenesis, the advent of novel and targeted therapeutics, and increasing collaborations between sarcoma investigators has helped move the field forward in the right direction. Here, we review the recent data on novel agents tested for the management of adult soft-tissue sarcomas, excluding gastrointestinal stromal tumors.
publisher Dove Medical Press
publishDate 2012
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3514064/
_version_ 1611937896584970240